Document Detail


Ranitidine for erosive oesophagitis: a double-blind, placebo-controlled study. Glaxo Erosive Esophagitis Study Group.
MedLine Citation:
PMID:  1420751     Owner:  NLM     Status:  MEDLINE    
Abstract/OtherAbstract:
A multicentre, randomized, double-blind, placebo-controlled study was conducted to evaluate the efficacy and safety of ranitidine 150 mg and 300 mg in 342 patients with erosive oesophagitis. Treatment was given four times daily, and continued for 12 weeks or until healing (that is, normal or only erythematous mucosa). Erosive oesophagitis healing rates, as determined by endoscopy, were significantly greater in ranitidine-treated patients by 4 weeks compared with those of placebo-treated patients. By 12 weeks, erosive oesophagitis healing rates were 83 and 81% for ranitidine-treated patients (150 and 300 mg, respectively) and 58% for placebo-treated patients (P less than or equal to 0.001, ranitidine vs. placebo). Symptomatic relief was achieved within 24 hours after starting either dosage of ranitidine. Heartburn frequency (P less than 0.001) and severity (P less than 0.001), as well as antacid consumed per week (P less than 0.001), were reduced in both ranitidine groups in comparison with placebo. Healing rates and symptom relief were similar in the two ranitidine groups. Both dosages of ranitidine were well tolerated. Ranitidine (150 mg) given four times daily appears to be as effective as 300 mg ranitidine given four times daily in patients with moderate to severe oesophageal erosions.
Authors:
W Roufail; A Belsito; M Robinson; C Barish; A Rubin
Publication Detail:
Type:  Clinical Trial; Comparative Study; Journal Article; Multicenter Study; Randomized Controlled Trial    
Journal Detail:
Title:  Alimentary pharmacology & therapeutics     Volume:  6     ISSN:  0269-2813     ISO Abbreviation:  Aliment. Pharmacol. Ther.     Publication Date:  1992 Oct 
Date Detail:
Created Date:  1992-12-18     Completed Date:  1992-12-18     Revised Date:  2006-11-15    
Medline Journal Info:
Nlm Unique ID:  8707234     Medline TA:  Aliment Pharmacol Ther     Country:  ENGLAND    
Other Details:
Languages:  eng     Pagination:  597-607     Citation Subset:  IM    
Affiliation:
Piedmont Research Associates, Winston-Salem, NC 27103.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:
Adult
Antacids / therapeutic use
Circadian Rhythm / physiology
Dose-Response Relationship, Drug
Double-Blind Method
Esophagitis / drug therapy*
Esophagus / drug effects,  physiology
Female
Heartburn / drug therapy,  prevention & control
Humans
Male
Ranitidine / adverse effects,  therapeutic use*
Chemical
Reg. No./Substance:
0/Antacids; 66357-35-5/Ranitidine

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  Oral or intravenous erythromycin has no effect on human distal colonic motility.
Next Document:  The effect of combined therapy with ranitidine and pirenzepine in the treatment of reflux oesophagit...